Ipilimumab (1mg/kg)

DRUG4 trials

Sponsors

Amr Mohamed MD, Gazi University, Fudan University, Sun Yat-sen University

Conditions

Colorectal Cancer (MSI-H)Esophageal Squamous Cell Carcinoma (ESCC)Gastroenteropancreatic Neuroendocrine NeoplasmGastroenteropancreatic Neuroendocrine TumorMetastatic Nonsmall Cell Lung CancerMixed Neuroendocrine-Non Neuroendocrine NeoplasmNeuroendocrine CarcinomaNonsmall Cell Lung Cancer, Stage IV

Phase 1

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

CompletedNCT05262556

Amr Mohamed MDGastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm, Neuroendocrine Carcinoma +1

Start: 2022-12-15End: 2025-10-27Updated: 2026-08-10

Phase 2

Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer

Not yet recruitingNCT07403877

Fudan UniversityColorectal Cancer (MSI-H)

Start: 2026-02-01End: 2034-12-31Target: 114Updated: 2026-02-11

Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer

RecruitingNCT07751055

Sun Yat-sen UniversityEsophageal Squamous Cell Carcinoma (ESCC)

Start: 2026-08-01End: 2030-12-31Target: 51Updated: 2026-08-07

Unknown Phase

Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)

RecruitingNCT07394062

Gazi UniversityNonsmall Cell Lung Cancer, Stage IV, Metastatic Nonsmall Cell Lung Cancer

Start: 2026-02-01End: 2028-02-01Target: 400Updated: 2026-05-18

Related Papers

NP-101 in Combination with Nivolumab and Ipilimumab in Metastatic Extra-pulmonary Neuroendocrine Carcinomas (EP-NECs): A Pilot Study.

2026-04-21